Back

Opportunistic aldosterone testing during hypokalemia as an alternative confirmatory test for primary aldosteronism

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Aldosterone and hypertension Secondary Hypertension ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Krishaa L

Singapore (Singapore)

5 More presentations in this session

Presentation thumbnail
Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death
Mr A. Angelico-Goncalves (Vila Nova de Gaia, PT)
Abstract Slides
Presentation thumbnail
Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study
Professor T. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Efficacy and safety of baxdrostat in resistant and uncontrolled hypertension: a systematic review and meta-analysis of randomised controlled trials
Ms J. Ferraz De Sousa (BR)
Presentation thumbnail
Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review
Doctor A. Bortolotto (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Aldosterone and hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Primary aldosteronism and aldosterone-driven hypertension
29 August 2025
thumbnail
Congress Presentation
Proportion of patients taking indapamide developing severe hypokalaemia
27 August 2021
thumbnail
Congress Presentation
Identification of predictors of response to initial oral combination therapy in WHO-functional class II or III PAH patients: A post-hoc analysis of the AMBITION study
28 August 2020
thumbnail
Congress Presentation
Optimizing aldosterone receptor antagonist therapy by sodium zirconium cyclosilicate in heart failure - OPRA-HF trial
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources